Literature DB >> 15114005

Construction of recombinant vaccinia virus: cloning into the thymidine kinase locus.

Chelsea M Byrd1, Dennis E Hruby.   

Abstract

Vaccinia virus (VV) has proven to be a very useful tool for the expression and analysis of foreign gene products. The most common method used to produce recombinant viruses involves the insertion of foreign genes into the thymidine kinase (TK) gene of the VV via homologous recombination. This is accomplished through the construction of a recombination plasmid containing the VV TK gene into the middle of which the gene of interest is inserted, appended to an efficient VV promoter element of the desired temporal class. Confluent monolayers of cells are infected with wild-type VV and transfected with the plasmid DNA to allow homologous recombination to occur. This inactivates the endogenous TK gene-producing TK-negative virus that can be biochemically selected, and recombinants can be identified by a variety of screening methods.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15114005     DOI: 10.1385/1-59259-789-0:031

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  8 in total

Review 1.  Activation and trafficking of CD8+ T cells during viral skin infection: immunological lessons learned from vaccinia virus.

Authors:  Samuel J Hobbs; Jossef F Osborn; Jeffrey C Nolz
Journal:  Curr Opin Virol       Date:  2017-10-25       Impact factor: 7.090

Review 2.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

3.  Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.

Authors:  Mark N Prichard; Kathy A Keith; Mary P Johnson; Emma A Harden; Alexis McBrayer; Ming Luo; Shihong Qiu; Debasish Chattopadhyay; Xuesen Fan; Paul F Torrence; Earl R Kern
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

4.  Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.

Authors:  J Weyer; I V Kuzmin; C E Rupprecht; L H Nel
Journal:  Epidemiol Infect       Date:  2007-06-22       Impact factor: 2.451

Review 5.  Viral gene therapy.

Authors:  P Mancheño-Corvo; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2006-12       Impact factor: 3.340

6.  Establishing elements of a synthetic biology platform for Vaccinia virus production: BioBrick™ design, serum-free virus production and microcarrier-based cultivation of CV-1 cells.

Authors:  Shuchang Liu; Ludmila Ruban; Yaohe Wang; Yuhong Zhou; Darren N Nesbeth
Journal:  Heliyon       Date:  2017-02-04

Review 7.  Viral Vector Vaccines against Bluetongue Virus.

Authors:  Luis Jiménez-Cabello; Sergio Utrilla-Trigo; Eva Calvo-Pinilla; Sandra Moreno; Aitor Nogales; Javier Ortego; Alejandro Marín-López
Journal:  Microorganisms       Date:  2020-12-25

8.  Engineering of Recombinant Sheep Pox Viruses Expressing Foreign Antigens.

Authors:  Olga Chervyakova; Elmira Tailakova; Nurlan Kozhabergenov; Sandugash Sadikaliyeva; Kulyaisan Sultankulova; Kunsulu Zakarya; Rinat A Maksyutov; Vitaliy Strochkov; Nurlan Sandybayev
Journal:  Microorganisms       Date:  2021-05-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.